Dacarbazine
- Generic Name
- Dacarbazine
- Drug Type
- Small Molecule
- Chemical Formula
- C6H10N6O
- CAS Number
- 4342-03-4
- Unique Ingredient Identifier
- 7GR28W0FJI
- Background
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
- Indication
For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Pancreatic Neuroendocrine Tumors (pNET), Advanced Soft Tissue Sarcoma, Hodgkin's Lymphoma, Metastatic Melanoma, Pheochromocytoma, Advanced Medullary thyroid cancer
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
- Conditions
- Hodgkin DiseasePeripheral T Cell Lymphoma
- Interventions
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT01716806
- Locations
- 🇺🇸
Wenatchee Valley Medical Center, Wenatchee, Washington, United States
🇺🇸James Cancer Hospital / Ohio State University, Columbus, Ohio, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
- Conditions
- Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1334
- Registration Number
- NCT01712490
Bevacizumab vs Dacarbazine in Metastatic Melanoma
- Conditions
- Metastatic Malignant MelanomaUnresectable Malignant Melanoma
- Interventions
- First Posted Date
- 2012-10-12
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Haukeland University Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT01705392
- Locations
- 🇳🇴
Haukeland University Hospital, Bergen, Norway
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)
- Conditions
- Malignant Melanoma
- Interventions
- First Posted Date
- 2012-10-11
- Last Posted Date
- 2020-05-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 540
- Registration Number
- NCT01704287
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
- Conditions
- N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma
- Interventions
- First Posted Date
- 2012-09-26
- Last Posted Date
- 2018-01-05
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 194
- Registration Number
- NCT01693068
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
🇩🇪Research site, München, Germany
🇺🇸Please contact the US Medical Information in, Rockland, Massachusetts, United States
A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma
- Conditions
- Advanced or Metastatic Liposarcoma or Leiomyosarcoma
- Interventions
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- Xian-Janssen Pharmaceutical Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT01692678
Dacarbazine and Carmustine in Metastatic Melanoma
- Conditions
- Melanoma Metastatic
- Interventions
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- Western Regional Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT01692691
- Locations
- 🇺🇸
Western Regional Medical Center, Goodyear, Arizona, United States
Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma
- First Posted Date
- 2012-09-07
- Last Posted Date
- 2015-06-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 21
- Registration Number
- NCT01681212
- Locations
- 🇯🇵
Local Institution, Chuo-shi, Yamanashi, Japan
Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma
- Conditions
- Advanced Melanoma
- Interventions
- First Posted Date
- 2012-06-07
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- University of Regensburg
- Target Recruit Count
- 136
- Registration Number
- NCT01614301
- Locations
- 🇩🇪
University of Regensburg, Regensburg, Bavaria, Germany
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma
- Conditions
- Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2012-04-03
- Last Posted Date
- 2018-10-29
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 100
- Registration Number
- NCT01569204
- Locations
- 🇩🇪
1st Dept. of Medicine, Cologne University Hospital, Cologne, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.